---
schema_version: "secwatch.filing_event.v1"
accession: "0000950123-21-010438"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:54:07.760651+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 net loss $18.4M; $255.6M IPO extends cash into late 2024

## Summary
- R&D expenses $14.6M (Q2 2020: $4.9M), G&A $3.5M ($0.5M) as headcount and lab activities expanded.
- Cash and equivalents $357.1M at June 30, 2021; plus $31M net from IPO underwriters' option exercise.
- NEK7 NLRP3 degrader program advanced into lead optimization; GSPT1 candidate selection anticipated before year-end.
- Appointed Filip Janku, M.D., Ph.D. as CMO; opened research centers in Boston Seaport and Basel.
- Anticipates at least one additional program entering lead optimization by end of 2021.

## SEC filing metadata
- accession: 0000950123-21-010438
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095012321010438/0000950123-21-010438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095012321010438/d167509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950123-21-010438
- JSON: https://secwatch.observer/filing/0000950123-21-010438.json
- Plain text: https://secwatch.observer/filing/0000950123-21-010438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.